Citius Pharma Announce Positive Topline Results For Pivotal Phase 3 Clinical Trial Of Mino-Lok
(RTTNews) - Biopharmaceutical company Citius Pharmaceuticals, Inc. (CTXR) announced Tuesday positive topline results of its pivotal Phase 3 clinical trial of Mino-Lok, a novel antibiotic lock solution designed to salvage catheters in patients with central line-associated infections (CLABSI) or catheter-related bloodstream infections (CRBSI).
The study met its primary endpoint with a statistically significant improvement in the time to failure event in patients receiving Mino-Lok compared to Control arm patients receiving clinician-directed anti-infective lock solution. The data demonstrate that Mino-Lok is well-tolerated.
The company said it looks forward to engage with the US Food and Drug Administration (FDA) to determine the optimal path forward for Mino-Lok, which is expected to offer a much-needed alternative to the current practice of catheter removal and replacement.
Canadian Market Settles Lower; TSX Sheds 0.6%
Dollar Turns In Mixed Performance Against Major Counterparts
Canadian Shares Notably Lower
Swiss Market Ends Lower On Growth Concerns
U.S. Dollar Strengthens After Strong Retail Sales Data
European Stocks Close Lower On Rate Cut Uncertainty, Growth Concerns
U.S. Business Inventories Inch Up Slightly Less Than Expected In September
